GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer Jun Liang , Jason R. Zbieg , Robert A. Blake , Jae H. Chang , Stephen Daly , Antonio G. DiPasquale , Lori S. Friedman , Thomas Gelzleichter , Matthew Gill , Jennifer M. Giltnane , Simon Goodacre , Jane Guan , Steven J. Hartman , Ellen Rei Ingalla , Lorn Kategaya , James R. Kiefer , Tracy Kleinheinz , Sharada S. Labadie , Tommy Lai , Jun Li , Jiangpeng Liao , Zhiguo Liu , Vidhi Mody , Neville McLean , Ciara Metcalfe , Michelle A. Nannini , Jason Oeh , Martin G. O’Rourke , Daniel F. Ortwine , Yingqing Ran , Nicholas C. Ray , Fabien Roussel , Amy Sambrone , Deepak Sampath , Leah K. Schutt , Maia Vinogradova , John Wai , Tao Wang , Ingrid E. Wertz , Jonathan R. White , Siew Kuen Yeap , Amy Young , Birong Zhang , Xiaoping Zheng , Wei Zhou , Yu Zhong , Xiaojing Wang Journal of Medicinal Chemistry(2021)
AI 理解论文
溯源树
样例